Recent developments in the diagnosis and management of tuberculosis by Sulis, G et al.
REVIEW ARTICLE OPEN
Recent developments in the diagnosis and
management of tuberculosis
Giorgia Sulis1,9, Rosella Centis2,9, Giovanni Sotgiu3,9, Lia D’Ambrosio2,4,9, Emanuele Pontali5,9, Antonio Spanevello6,7, Alberto Matteelli1,
Alimuddin Zumla8 and Giovanni Battista Migliori2
Tuberculosis (TB) is a major public health issue worldwide, with ~ 9.6 million new incident cases and 1.5 million deaths in 2014. The
End-TB Strategy launched by the World Health Organization in the context of the post-2015 agenda aims to markedly abate the
scourge of TB towards global elimination, by improving current diagnostic and therapeutic practices, promoting preventative
interventions, stimulating government commitment and increased ﬁnancing, and intensifying research and innovation. The
emergence and spread of multidrug-resistant strains is currently among the greatest concerns, which may hinder the achievement
of future goals. It is crucial that primary healthcare providers are sufﬁciently familiar with the basic principles of TB diagnosis and
care, to ensure early case detection and prompt referral to specialised centres for treatment initiation and follow-up. Given their
special relationship with patients, they are in the best position to promote educational interventions and identify at-risk individuals
as well as to improve adherence to treatment.
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INTRODUCTION
Tuberculosis (TB) is still a ﬁrst-class public health priority,
representing the leading cause of death at global level.
According to the World Health Organization (WHO), as many as
9.6 million new incident cases and 1.5 million deaths are
estimated to have occurred in 2014, with Africa and Asia
carrying the greatest burden. Of note, nearly half of the global
TB cases are reported in only three countries (India, Indonesia
and China).1
TB is a well-known poverty-related disease, often associated
with social marginalisation and ﬁnancial deprivation.2,3 However,
the most important risk factor for TB remains the human
immunodeﬁciency virus (HIV), with a signiﬁcant proportion of
HIV/AIDS mortality still attributable to TB.4–6 About 12% of all TB
patients were estimated to be HIV infected in 2014, and 25% of TB
deaths occurring in the same year involved people living with
HIV.1 Sub-Saharan Africa accounts for the largest proportion of
TB/HIV cases worldwide, in spite of the increasing antiretroviral
treatment coverage as well as improvements in access to care in
the most affected countries.7–11
Non-communicable diseases such as diabetes mellitus are
gaining attention as potential risk factors for developing active
TB in both poor and wealthy settings, thus raising new issues on
prevention and early diagnosis.12,13
In spite of its considerable global impact, TB is preventable and
curable that makes the ﬁght against the disease a highly cost-
effective intervention.14 However, the emergence and spread of
multidrug resistances may hinder the achievement of goals, as the
detection and treatment of multi- and extensively drug-resistant
TB (M/XDR-TB) are still a major concern.15,16
Around TB, control and elimination programmes have
been created, requiring a coordinated effort of both clinicians
and public health ofﬁcers, to ensure that infectious cases are
diagnosed and treated rapidly, and infected individuals belonging
to high-risk groups are adequately managed.
The aim of this review paper is to provide an overview and
elimination strategies, and to describe the basics of present and
future challenges in TB diagnosis, treatment and prevention under
a clinical perspective.
TB CONTROL FROM THE BEGINNING TO THE END-TB
STRATEGY
The global agenda beyond 2015 stands on seventeen Sustainable
Development Goals (SDGs), one of which (SDG 3) is speciﬁcally
addressed to health issues and calls for ending the major global
epidemics including that of TB.17,18 The WHO’s End-TB Strategy,
that was approved by the World Health Assembly in May 2014 and
further developed throughout 2015 to come into effect in January
2016, clearly points to the global elimination of TB.19
However, it took over 20 years to get to this point at strategic
level, after achieving several successes in the ﬁght against the
disease in the most affected areas.14 The recognition of TB as a
global emergency only came in 1993 when the WHO ﬁrst declared
the need for great efforts and strong commitment at all levels to
address the epidemic.20,21 About a year later, the ﬁrst TB-control
strategy (called directly observed therapies) was launched.
1Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV and TB elimination, University of Brescia, Brescia, Italy; 2WHO Collaborating Centre for TB
and Lung Diseases, Maugeri Institute, IRCCS, Italy; 3Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari—Research, Medical
Education and Professional Development Unit, AOU Sassari, Sassari, Italy; 4Public Health Consulting Group, Lugano, Switzerland; 5Department of Infectious Diseases, Galliera
Hospital, Genova, Italy; 6Pneumology Unit, Maugeri Institute, IRCCS, Tradate, Italy; 7Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy and
8Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
Correspondence: GB Migliori (giovannibattista.migliori@fsm.it)
9These authors contributed equally to this work.
Received 7 June 2016; revised 20 September 2016; accepted 22 September 2016
www.nature.com/npjpcrm
Published in partnership with Primary Care Respiratory Society UK
The adoption and adaptation of this framework in nearly all
countries led to a signiﬁcant improvement in case detection and
to the scale-up of a standardised anti-TB treatment.22 The
constitution of the Global Fund in 2002 contributed to further
promote the implementation of this strategy at national level by
guiding an appropriate allocation of available funds towards the
expansion of access to diagnosis and care. Of note, the Global
Fund currently accounts for as much as 72% of the total ﬁnancing
for TB-related interventions, followed by the government of
the United States (14%), other governments (8%) and other
multilateral organisations (6%).
In 2006, the Stop-TB Strategy replaced the former one by
strengthening its basic components to reach more ambitious
targets within the following decade.14,23,24 Special attention was
reserved to TB/HIV co-infection that required a concerted action
together with the HIV/AIDS programme, as well as to the rapidly
emerging MDR-TB epidemic. The main objectives were to reverse
the trend in TB incidence and to halve TB prevalence and
mortality worldwide by 2015 as compared with that in 1990.
According to the current estimates, all these goals have been fully
met, although the declining rate of TB incidence is still too slow
(~1.5–2% per year on average).
It is in this scenario that the End-TB Strategy was ﬁnally
designed, thus bringing a considerable change in the approach to
disease control, by establishing increasing links with the socio-
economic and political dimensions of the problem.19 The new
goals are far more ambitious than the previous ones and point to
the global elimination of the disease, starting from low-income
countries that are closer to the target. This vision stands on the
growing awareness that TB cannot be eliminated from a single
area unless all the countries collaborate together towards a shared
objective and through a common strategic plan. This approach is
very well summarised in the three basic pillars of End-TB:
(1) promote integrated patient-centred care and prevention;
(2) foster bold policies and supportive systems; and (3) encourage
intensiﬁed research and innovation. The goals for 2035 include a
95% reduction in TB-related mortality and 90% decline in TB
incidence (corresponding to o10 cases per 100,000 population
globally), alongside with the complete abolition of catastrophic
costs for TB-affected patients and their families.19
For the ﬁrst time in the history of TB-control strategies, a great
emphasis is put on the importance of research, which is deﬁnitely
the key to changing the course of the epidemic; without new
diagnostics, new drugs and effective vaccines, the global ﬁght
against TB is bound to fail.25
Another critical novelty of this post-2015 agenda lies in the
pre-eminent role of prevention, although prompt diagnosis and
treatment remain the major priority, especially in high TB-burden
settings. In accordance with this concept, a speciﬁc framework for
TB elimination from low-incidence countries was developed
besides the End-TB strategy, aimed at stimulating governments
and national health authorities to take action against the
submerged reservoir of latent TB infection (LTBI).26–28
A recent study conducted in Europe has demonstrated that
management of LTBI is still far to be applied as per national and
international recommendations.28 General practitioners have a
pre-eminent role in promoting screening for LTBI among contacts
of TB cases and other at-risk populations, and treatment of latently
infected individuals within the patient-centred vision recently
promoted by the International Standards for Tuberculosis Care (ISTC)
and European union Standards for Tuberculosis Care (ESTC).29–31
It is important to underline that the End-TB Strategy is aimed at
serving all countries, although the WHO LTBI guidelines target
high- and middle-income countries, and the TB Elimination
framework is addressed to low-incidence countries. In this context,
we observe low-income countries facing the elimination phase
(e.g., Cuba) and European Union countries (e.g., Romania) having
medium-level incidence.
TB DIAGNOSTICS: PAST, PRESENT AND FUTURE
TB should be suspected when at least one of four suggestive
symptoms is reported (long-lasting fever, cough of 2-week
duration or more, night sweats and weight loss). Epidemiological
aspects, such as history of contact with a pulmonary TB case
and/or exposure to other risk factors for TB acquisition or
reactivation, also need to be carefully evaluated.32 Special
attention should be devoted to patients affected by chronic
conditions such as diabetes mellitus who may experience milder
symptoms that can be often misinterpreted as related to their
underlying disease. The diagnosis of TB must be conﬁrmed by
detecting the causative agent (Mycobacterium tuberculosis, MTB) in
an appropriate biological specimen.
Direct microscopic examination is a fast and inexpensive
method to identify acid-fast bacilli through the use of
Ziehl–Neelsen staining; however, it is limited by poor sensitivity
and the inability to discriminate between mycobacterial species,
which can be a relevant issue especially among children and
immunocompromised individuals. Fluorescence or light-emitting
diode microscopy may be an alternative to traditional microscopy
with a moderate improvement in sensitivity (+10%) but also
slightly higher costs and the need for well-trained technicians
(Figure 1).33 The poorest performances of microscopic examina-
tion for the diagnosis of TB are usually observed in high-risk
groups such as people living with HIV who often yield a false-
negative result. For this reason, WHO currently recommends a
biomolecular test as the initial diagnostic tool in case of TB
suspect.34,35 Among the several commercially available nucleic
acid ampliﬁcation tests, Xpert MTB/Rif (Cepheid, Sunnyvale,
CA, USA) is the most efﬁcient and suitable for implementation in
resource-constrained settings (at the point-of-care level), as it does
not require any sophisticated laboratory facility, is fully automated
and provides the results in o2 h (Figure 2).36 As compared with
smear microscopy, it is characterised by higher sensitivity and
speciﬁcity on both respiratory and extrapulmonary specimens,
and it allows to identify MTB and detect mutations associated to
rifampicin resistance, which makes it a good proxy for the
detection of MDR strains.37–39
Figure 1. Light-emitting diode ﬂuorescence microscopy.
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Nevertheless, culture remains the gold standard technique for
the diagnosis of TB, even though its large-scale use is limited by
the long waiting time due to the slow growth rate of mycobacteria
(~2–6 weeks in liquid media) with consequent diagnostic delays;
furthermore, the need for biosafety level 3 laboratory infrastruc-
tures and highly skilled laboratory technicians who are often
lacking especially in resource-constrained settings is another
signiﬁcant limitation.40 Drug susceptibility testing on solid or
liquid culture is essential to conﬁrm a diagnosis of MDR-TB, but its
availability in low-income and high-burden areas is far less than
is needed. Molecular tests, such as GenoType MTBDRplus, a
line probe assay, that rapidly detects TB bacteria and identiﬁes
resistances to the most important ﬁrst-line drugs (rifampicin and
isoniazid) and to some second-line molecules in its latest version,
are often used as substitutes for conventional drug susceptibility
testing, although their implementation is still challenged by high
costs and complex technical requirements.41,42 The MTBDRsl
molecular test has been recently endorsed by WHO.43 Whole-
genome sequencing is under investigation as a potentially
promising tool to detect relevant mutations that could predict
drug resistance and help to design individualised therapeutic
regimens.44
Tuberculin skin test and interferon-gamma release assay are
currently recommended for the diagnosis of LTBI, but have a
marginal role in the detection of TB cases, as they cannot
distinguish between active and latent infection and may be
inﬂuenced by the patient’s immune status. These tests will be
further discussed in another section of this paper.
A relevant proportion of the estimated 9.6 million TB cases
worldwide is not detected either because of limited access to
healthcare facilities or because of the unavailability of appropriate
diagnostic methods. Reaching the ‘missed’ 3 million cases is
among the top ﬁve priorities to eliminate TB, and to do so, new
point-of-care tests are urgently needed.45 Research is ongoing to
develop a diagnostic tool that meets the basic characteristics of
rapidity, low cost, high sensitivity and technical simplicity. There is
increasing interest in the mycobacterial lipoarabinomannan (LAM)
urinary detection method (and its ‘lateral ﬂow’ variant) that may be
very useful in diagnosing active TB. LAM is an antigen located in
mycobacterial outer cell wall, and it is thought to be present in
individuals with active disease but not in those with LTBI,
irrespective of their immunological conditions.46–48 This test, that
can be easily performed in peripheral centres leading to better
access to care, may prove advantageous for ruling out TB in
children (given the simplicity of urine collection compared with
other clinical samples) and facilitate the identiﬁcation of extra-
pulmonary forms of TB. Unfortunately, no information is provided
about the mycobacterial species and the drug susceptibility pattern
of the infecting strain that is a considerable limit when dealing with
high-risk populations and/or in high MDR-TB-burden contexts.
Based on the current evidence, the WHO does not recommend the
use of urinary LAM detection in patients with presumptive TB with
the exception of HIV-positive individuals with low CD4+ counts or
who are seriously ill, who may beneﬁt from this test in addition to a
well-established diagnostic tool.49 Other studies are underway to
investigate on the role of mycobacterial metabolic products in
exhaled breaths (the so-called ‘volatile organic compounds’) in the
diagnosis of TB in symptomatic patients.50
It is of paramount importance that general practitioners are
familiar with the standards for diagnosis of TB, as the ‘dangerous’
case of TB is the undetected case, and rapid diagnosis (coupled
with effective treatment) is the essence of TB control.30,31
TB TREATMENT
Anti-TB treatment aims to cure the patient, prevent complications
and death, avoid relapses, reduce the transmission potential to
susceptible individuals, and limit the emergence and spread of
drug-resistant strains. For all these reasons, the therapeutic
approach to TB requires the use of multiple drugs. Treatment
should include an intensive phase aimed at markedly decreasing
the bacterial burden, followed by a ‘sterilising’ consolidation
phase, with an overall duration of at least 6 months. Longer
treatments may be required in selected situations, such as in
patients with extensive bone involvement or those with cerebral
tuberculomas.51 The ﬁrst-line standard regimen that is currently
recommended for drug-susceptible TB is based on a 2-month
intensive phase with four drugs (isoniazid, rifampicin,
pyrazinamide and ethambutol; HRZE) followed by a 4-month
consolidation phase with two drugs (isoniazid and rifampicin; HR).
Dose adjustment is required for children according to body
weight, but the regimen composition remains the same.52
Comorbidities do not justify any changes in the therapeutic
approach to TB, although potential drug–drug interactions should
be carefully evaluated and managed if necessary. Optimal
adherence throughout the whole duration of treatment is crucial,
as poor compliance is among the major causes of treatment
failure, being associated with a high risk of resistance selection.
Hospitalisation of drug-susceptible TB patients is usually
unnecessary, except for those presenting with severe clinical
manifestations or in case of signiﬁcant social fragility, which may
considerably interfere with monitoring and compliance.
Although the treatment success rate of drug-susceptible TB
exceeds 85% at global level even in high-burden settings,
the outcome is much poorer for patients with drug-resistant TB
(50% on average).1 MDR-TB is deﬁned as resistance to at least
rifampicin and isoniazid, whereas XDR-TB includes MDR-TB cases
with additional resistances to any ﬂuoroquinolone and any of the
injectable drugs. The treatment outcomes are lower in XDR-TB
cases (40% on average), but they may be as low as 19% when the
disease is sustained by MTB strains with a resistance pattern
beyond XDR.53,54
Figure 2. Xpert MTB/Rif.
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A revision of the former classiﬁcation of anti-TB drugs in ﬁve
different groups (i.e., all ﬁrst-line agents belonged to group 1,
whereas groups 2–5 contained second-line molecules
characterised by lower efﬁcacy and a less favourable safety
proﬁle) has been recently approved based on the current
evidence on each drug (Table 1).43,55,56 The conventional regimen
for rifampicin resistant or MDR-TB currently recommended by the
WHO consists of at least ﬁve effective anti-TB drugs during the
intensive phase, including pyrazinamide and four core second-line
anti-TB drugs (one chosen from group A, one from group B and at
least two from group C2; if the minimum number of effective anti-
TB drugs cannot be reached by using agents from groups A to C
alone, drugs from group D2 or, if not possible, from group D3 are
added to bring the total to ﬁve); agents from group D1 are added
if they are considered to add beneﬁt (e.g., high-dose isoniazid in
patients without high-level isoniazid resistance; Table 2).
Up to now, a total treatment duration of 18–20 months has
been recommended for most MDR-TB patients, but the optimal
duration of treatment is actually a matter of debate.55 Shorter
regimens (lasting o12 months) based on a combination of likely
effective second-line drugs have recently been evaluated, ﬁrst in
Bangladesh and then in other countries (mostly in Africa), showing
very promising results.57–59 The WHO guidelines have been
updated in May 2016 in accordance with these ﬁndings, including
a recommendation for the use of shorter treatment options if
speciﬁc conditions are met.43 In particular, patients who were
previously exposed to second-line agents, pregnant women,
extrapulmonary TB cases, XDR-TB patients or those with intoler-
ance to any of the regimen components cannot be considered
eligible. Given that treatment of M/XDR-TB is very expensive, a
signiﬁcant reduction of costs and a higher rate of patients’
retention on care are among the major advantages of this
innovative approach.60,61 However, the correct management of
such regimens is pivotal in order not to promote the selection of
further resistances, which makes it even more important to
reserve M/XDR-TB case management only to highly experienced
clinicians based on international guidelines.62,63
Over a 40-year period, only two new molecules (bedaquiline
and delamanid) have been developed and approved by WHO for
selected cases.64–68 Some other drugs (such as carbapenems and
linezolid) have been recently repurposed for the use in M/XDR-TB
treatment and are currently classiﬁed as group 5 drugs.69–73 All
these agents require a careful management in the context of
individualised regimens under close clinical and laboratory
monitoring.62
WHO and partners have devoted speciﬁc attention to the
management of paediatric TB in the last few years because of the
speciﬁc difﬁculties in diagnosing and managing treatment in this
speciﬁc population.52
Table 1. Anti-TB drugs recommended for the treatment of rifampicin-
resistant and multidrug-resistant TBa (from ref. 43)
Group name Anti-tuberculosis drugs Abbreviation
A. Fluoroquinolonesb Levoﬂoxacin Lfx
Moxiﬂoxacin Mfx
Gatiﬂoxacin Gfx
B. Second-line
injectable agents
Amikacin Am
Capreomycin Cm
Kanamycin Km
(Streptomycin)c (S)
C. Other core
second-line agentsb
Ethionamide/Prothionamide Eto/Pto
Cycloserine/Terizidone Cs/Trd
Linezolid Lzd
Clofazimine Cfz
D. Add-on agents (not part of the core MDR-TB regimen)
D1 Pyrazinamide Z
Ethambutol E
High-dose isoniazid Hh
D2 Bedaquiline Bdq
Delamanid Dlm
D3 p-Aminosalicylic acid PAS
Imipenem cilastatind Ipm
Meropenemd Mpm
Amoxicillin clavulanated Amx-Clv
(Thioacetazone)e (T)
aThis regrouping is intended to guide the design of conventional
regimens; for shorter regimens lasting 9–12 months, the composition is
usually standardised.
bMedicines in groups A and C are shown by decreasing order of usual
preference for use.
cAlthough streptomycin is not usually included with the second-line drugs,
it can be used as the injectable agent of the core MDR-TB regimen if none
of the three other agents can be used and if the strain can be reliably
shown not to be resistant. Resistance to streptomycin alone does not
qualify for the deﬁnition of extensively drug-resistant TB (XDR-TB).
dCarbapenems and clavulanate are meant to be used together; clavulanate
is only available in formulations combined with amoxicillin.
eHIV status must be tested and conﬁrmed to be negative before
thioacetazone is started.
Table 2. Conventional treatment regimens for rifampicin-resistant or MDR-TB (adapted from ref. 43)
World Health Organization recommendations
In patients with RR or MDR-TB, a regimen with at least ﬁve effective anti-TB during the intensive phase is recommended, including:
● Pyrazinamide
● Four core second-line anti-TB drugs:
One from group A (Lfx, Mfx, Gfx)
One from group Ba (Am, Cm, Km, (S))
At least two from group C (Eto/Pto, Cs/Trd, Lzd, Cfz)
If the minimum of effective TB medicines cannot be composed as above, an agent from group D2 (Bdq, Dlm) and other agents from D3 (PAS, Ipm,
Mpm, Amx-Clv, T) may be added to bring the total to ﬁve.
In patients with RR or MDR- TB, it is recommended that the regimen be further strengthened with high-dose isoniazid and/or ethambutol
It is recommended that any patient—child or adult—with RR-TB in whom isoniazid resistance is absent or unknown be treated with a
recommended MDR-TB regimen, either a shorter MDR-TB regimen, or if this cannot be used, a conventional MDR-TB regimen to which isoniazid is
added.
Abbreviations: MDR-TB, multidrug-resistant tuberculosis; RR, rifampicin resistant.
aIn children with non-severe disease, group B anti-TB drugs may be excluded.
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Although no recommendations have been issued up to now for
the use of bedaquiline and delamanid in the paediatric population
due to the lack of scientiﬁc evidence (controlled clinical trials are
still ongoing), encouraging ﬁndings on delamanid have emerged
from some pharmacokinetic studies conducted on children over
6 years of age.74–76
To our knowledge, co-administration of these two new drugs in
the same patient has only been described for sporadic adult cases,
and WHO is not recommending their association as evidence does
not allow it yet.77–79 Rigorous criteria have been recommended to
ensure the appropriate management of such regimens in
well-recognised reference centres.63
Therapeutic drug monitoring has been proposed as a
potentially useful tool for treatment individualisation especially
for selected patient categories such as those at high risk for
drug–drug interactions or drug malabsorption and/or under-
dosing, thus limiting the risk of adverse events and leading to a
reduction of costs.60,61 However, a standardised protocol has not
been deﬁned yet and further investigations are needed to better
assess the role of therapeutic drug monitoring in the routine
clinical practice.80–86 Nevertheless, designing the best therapeutic
regimen for a single patient is likely to remain quite a challenging
task until more effective and less toxic drugs are not be
available.87
In the complex scenario of the M/XDR-TB epidemic,
a web-based free-of-charge tool jointly developed by the
European Respiratory Society and the WHO was launched
in 2012 to help clinicians facing the challenges of drug
resistance management by providing tailored expert opinion on
difﬁcult-to-treat cases (www.tbconsilium.org).88
As any TB patient is potentially infectious till appropriate
treatment has been initiated, appropriate infection control
measures need to be ensured, through managerial, administrative
and environmental interventions.89–91 A recent European study
has shown that even in qualiﬁed centres, infection control
practices are sub-optimally applied, further contributing to
circulation of MTB among other patients, staff, visitors and
ultimately within the community.89–91
The contribution of general practitioners in ensuring correct
treatment of TB cases, in collaboration with the specialists who
usually initiate it, is of paramount importance, due to the special
relationship they have with their patients and the possibility to
educate, foster adherence, monitoring treatment and ensuring
directly observed therapy.30,31
LTBI AND TB PREVENTION
The natural history of TB begins with the acquisition of infection
through the inhalation of MTB that subsequently enters a
replication cycle and disseminates within the host, whose immune
system usually reacts and leads to containment of viable bacilli.
The result of this process is asymptomatic LTBI, a condition in
which TB bacteria remain in the body in a quiescent state, without
making any damage and therefore without causing transmission
to other susceptible individuals.92
Although it is substantially impossible to test everybody,
mathematical models estimate that about a third of the global
population has LTBI, an incredibly large pool from which TB cases
actually arise each year.93
Most people remain latently infected for their whole life, often
unaware of their condition, and do not constitute a public health
problem. However, ~ 5–15% of them may experience reactivation
at some point in time, thus becoming TB cases with transmission
potential. It is thought that reactivation actually leads to as many
as 80% of the global TB cases, which is particularly true in
low-incidence countries. The risk of progression from latent
infection to active disease is considerably higher in some
populations that therefore requires special attention and targeted
interventions.94 The management of LTBI is now fully recognised
as a core component of the End-TB Strategy, as demonstrated by
the recent development of speciﬁc guidelines by WHO.95 Among
the main objectives of this document is the deﬁnition of the
so-called ‘high-risk groups’, i.e., those who are more likely to
undergo TB reactivation. People living with HIV and children
under 5 years of age who are household or close contacts of a TB
case represent the priority target, being the most vulnerable
categories in any setting. All such individuals should be
systematically put on LTBI treatment whenever active TB is
excluded.52,96–98 Other populations should be carefully considered
according to the local resources in high- and upper middle-
Table 3. Recommended treatment options for LTBI (adapted from
ref. 95)
Treatment options for LTBI
6-month isoniazid
or 9-month isoniazid
or 3-month regimen of weekly rifapentine plus isoniazida
or 3–4 months isoniazid plus rifampicina
or 3–4 months rifampicin alonea
aRifampicin- and rifapentine-containing regimens should be prescribed
with caution to people living with HIV who are on antiretroviral treatment
due to potential drug-to-drug interactions.
Table 4. Recommendations for LTBI screening and treatment in different high-risk population groups in high- and upper middle-income countries
with low TB incidence (adapted from ref. 95)
In high-income and upper middle-income countries with estimated TB incidence o100 per 100,000 population
● Systematic testing and treatment of LTBI should be performed in people living with HIV, adult and child contacts of pulmonary TB cases,
patients initiating anti-tumour necrosis factor (TNF) treatment, patients receiving dialysis, patients preparing for organ or haematologic
transplantation, and patients with silicosis. Either interferon-gamma release assays (IGRAs) or Mantoux tuberculin skin test (TST) should be
used to test for LTBI.
● Systematic testing and treatment of LTBI should be considered for prisoners, health workers, immigrants from high TB-burden countries,
homeless persons and illicit drug users. Either IGRA or TST should be used to test for LTBI.
● Systematic testing for LTBI is not recommended in people with diabetes, people with harmful alcohol use, tobacco smokers and in
underweight people unless they are already included in the above recommendations.
For resource-limited countries and other middle-income countries that do not belong to the above
● People living with HIV and children below 5 years of age who are household or close contacts of people with TB and who, after an appropriate
clinical evaluation, are found not to have active TB but have LTBI should be treated.
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income countries with low TB incidence; they include candidates
to tumour necrosis factor-alpha inhibitor treatment, patients
with silicosis, transplant recipients and patients requiring
haemodialysis, for whom systematic testing and treatment is
strongly recommended.95 In addition to those mentioned above,
other at-risk groups may be identiﬁed such as migrants from high
TB-burden countries, prisoners, healthcare workers, homeless
people or injection drug users, who may also beneﬁt from LTBI
treatment if feasible. Current diagnostic tests do not allow direct
identiﬁcation of dormant TB microorganisms in a latently infected
subject. For this reason, LTBI can only be diagnosed by evaluating
the immunological response to in vivo or in vitro stimulation by
mycobacterial antigens, which is the underlying principle of the
tuberculin skin test and interferon-gamma release assays.
According to current recommendations, tuberculin skin test
and interferon-gamma release assays can be considered
interchangeable, and tuberculin skin test should not replace
interferon-gamma release assays for LTBI diagnosis in low- and
middle-income settings. Both tests are limited by the inability to
predict the risk of reactivation and cannot distinguish between
latent infection and active disease.95,99 In case of a positive result
to any of them, active TB must be reasonably ruled out before
starting LTBI treatment, which is essential to avoid the selection of
drug resistances. A 6-month course of daily isoniazid is the only
currently recommended option for treatment in resource-limited
settings, with life-long administration encouraged among people
living with HIV in high TB transmission areas.96,100 Alternative
therapeutic regimens can be considered in high-income countries
for patients other than children and HIV-positive individuals
(Tables 3 and 4).95
CONCLUDING REMARKS
Current data on TB epidemiology suggest that targeted sensitisa-
tion initiatives are still largely needed to raise awareness among
clinicians on the importance of this disease. Thinking about TB is
the ﬁrst step to ﬁght TB, as early diagnosis and prompt initiation of
treatment are essential to achieve the best outcome and limit the
risk of transmission to other individuals. Special attention should
be paid to the so-called ‘high-risk populations’, who are more
likely to be infected with TB bacteria and to develop an active
disease, thus maintaining the vicious cycle of transmission within
the community. Primary care providers are the key to both control
and elimination strategies, which, at the end, are based on correct
diagnosis and treatment of TB patients and latently infected
individuals.
Primary healthcare providers, in fact, have a crucial role in the
identiﬁcation of at-risk subjects who may beneﬁt from LTBI
screening and treatment, as well as of TB suspects who should be
referred to specialised centres for further investigations and
management. Empirical use of anti-TB drugs outside the context
of reference TB care facilities should be strongly discouraged to
avoid the selection of drug resistances, which makes the therapeutic
management of affected patients much more challenging.
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